Related references
Note: Only part of the references are listed.JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects
Benjamin Klein et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)
Perception of the coronavirus pandemic by patients with atopic dermatitis - Results from the TREATgermany registry
Claudia Helmert et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)
The role of the skin microbiome in atopic dermatitis - correlations and consequences
Regina Foelster-Holst
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)
The HOME Core outcome set for clinical trials of atopic dermatitis
Hywel C. Williams et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Thomas Bieber
NATURE REVIEWS DRUG DISCOVERY (2022)
An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis
T. Werfel et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Update Systemic treatment of atopic dermatitis of the S2k-guideline on atopic dermatitis
Thomas Werfel et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2021)
Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needs
Matthias Augustin et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2021)
Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum
Lianghua Bin et al.
ALLERGY (2021)
Eczema herpeticum in atopic dermatitis
Stephan Traidl et al.
ALLERGY (2021)
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Kristian Reich et al.
LANCET (2021)
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
Emma Guttman-Yassky et al.
LANCET (2021)
Status report on the atopic dermatitis registry TREATgermany
D. Siegels et al.
ALLERGOLOGIE (2021)
Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients
M. Seegraeber et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany
A. Heratizadeh et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric L Simpson et al.
LANCET (2020)
TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries
L. A. A. Gerbens et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Lawrence F. Eichenfield et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses
Stephan Traidl et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials
Patrick Fleming et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Identification of novel gene signatures in patients with atopic dermatitis complicated by eczema herpeticum
Lianghua Bin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials
Jochen Schmitt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting
Jochen Schmitt et al.
ALLERGY (2012)
Staphylococcus aureus α-toxin modulates skin host response to viral infection
Lianghua Bin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Genetic Variants in Interferon Regulatory Factor 2 (IRF2) Are Associated with Atopic Dermatitis and Eczema Herpeticum
Pei-Song Gao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum
Pei-Song Gao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum
Pei-Song Gao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Phenotype of atopic dermatitis subjects with a history of eczema herpeticum
Lisa A. Beck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Risk factors of atopic dermatitis patients for eczema Herpeticum
Wenming M. Peng et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Viral infections in atopic dermatitis: Pathogenic aspects and clinical management
A Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
Predisposing factors and clinical features of eczema herpeticum: A retrospective analysis of 100 cases
A Wollenberg et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis
S Reitamo et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2002)
Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment
J Lubbe et al.
DERMATOLOGY (2000)